DESVENLAFAXINE SUCCINATE

Post-LOE

desvenlafaxine succinate

ANDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2026
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that…

Clinical Trials (5)

NCT01443208Phase 1Completed

Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet

Started Nov 2011
36 enrolled
Major Depressive Disorder
NCT01432457Phase 4Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Started Oct 2011
924 enrolled
Major Depressive Disorder
NCT01189500Phase 4Completed

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Started Aug 2010
30 enrolled
Pharmacokinetics
NCT01188668Phase 4Completed

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Started Aug 2010
38 enrolled
PharmacokineticsCytochrome P-450 CYP2D6CYP3A4 Protein, Human
NCT01121484Phase 4Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Started Jun 2010
439 enrolled
Major Depressive Disorder